The Rapid Growth of CRISPR Startup Mammoth Biosciences
Biotech startup Mammoth Biosciences officially achieved “unicorn” status in September 2021. After securing US$195 million in funding, it now has a total valuation of more than US$1 billion.
The financing for the California-based company comprises a US$150 million in its Series D round, following a $45 million in Series C funding in late 2020 led by venture capitals and investment firms.
The Rapid Growth of CRISPR Startup Mammoth Biosciences Read More »
Biotech startup Mammoth Biosciences officially achieved “unicorn” status in September 2021. After securing US$195 million in funding, it now has a total valuation of more than US$1 billion.
The financing for the California-based company comprises a US$150 million in its Series D round, following a $45 million in Series C funding in late 2020 led by venture capitals and investment firms.


